Theratyping is moving cystic fibrosis care closer to variant-level treatment selection
The arrival of CFTR modulators has altered the course of cystic fibrosis for many people, but a large gap remains between approved therapies and the full genetic diversity of the disease. Rare and ultra-rare variants often sit outside the reach of conventional clinical trials, leaving clinicians with limited evidence when they try to match a patient to a drug. Theratyping addresses that gap by testing an individual’s own cells ex vivo and measuring whether a modulator restores CFTR function. In practice, the approach turns biology into a treatment readout rather than relying only on genotype labels.
This review places theratyping at the center of a broader shift toward precision medicine in cystic fibrosis. The argument is straightforward: if a mutation is uncommon enough to evade a trial, a functional assay can still reveal whether the patient’s tissue responds to a candidate therapy. For people living with rare variants, that is not an abstract research concept. It can determine whether a medication is likely to be useful at the bedside or whether the search needs to continue.
Functional testing fills the evidence gap left by rare CF variants
Cystic fibrosis remains a disease of broad molecular heterogeneity, even as modulator therapy has changed outcomes for many patients with eligible mutations. Genetic classification alone does not always predict treatment response with enough precision to support individual prescribing decisions. Some variants alter protein processing, some impair trafficking, and others change channel gating or reduce protein production altogether. The therapeutic logic differs across those mechanisms, which is why a one-size-fits-all approach fails for many rare genotypes.
Theratyping offers a way to measure the end result directly. Patient-derived cells can be exposed to modulators, and investigators can examine whether CFTR activity improves in a meaningful way. This makes the assay especially useful when clinical trials are impractical because the target population is too small or too dispersed. The value is not limited to rare mutations, either. A functional response can help clarify why two patients with apparently similar variants may not experience the same biological effect from the same drug.
A single ex vivo result can change the treatment conversation.
That kind of direct functional evidence matters because cystic fibrosis is not only a genetic diagnosis; it is a disease of disrupted ion transport, dehydrated airway surface liquid, impaired mucociliary clearance, and chronic infection. A modulator that restores channel function changes the biology driving mucus stasis and progressive lung injury. Theratyping is valuable precisely because it links the molecular defect to the drug’s effect on the relevant pathway.
Disease models are expanding beyond traditional cell systems
The review emphasizes that theratyping now sits within a fast-moving ecosystem of disease models. Classic in vitro systems remain important, but newer platforms are broadening what can be measured and how closely the assay reflects human physiology. Organoids, airway epithelial cultures, and related ex vivo systems allow investigators to observe tissue behavior in a setting that preserves patient-specific biology. These models can capture responses that would be missed in simpler cell lines.
The field is also moving toward technologies designed to improve mechanistic insight and preclinical predictivity. Organ-on-a-chip systems, in particular, are attractive because they can recreate features of airway architecture, fluid flow, and cell-to-cell interaction that matter in cystic fibrosis pathobiology. The review frames these approaches as part of a refinement process: better human relevance, less reliance on less predictive models, and a stronger bridge between laboratory findings and clinical application.
Animal models still have a role in understanding disease mechanisms, but the review makes clear that their limitations are equally important. No model fully reproduces the complexity of human cystic fibrosis across genotype, airway remodeling, infection burden, and treatment response. The ethical framework of Replacement, Reduction, and Refinement provides a practical way to think about that problem. If a human-relevant ex vivo platform can answer the question with greater fidelity, it may reduce the need for less informative experiments while improving translational utility.
Why theratyping could matter beyond cystic fibrosis
Cystic fibrosis has become a paradigmatic example of how rare-disease medicine can evolve when functional biology is placed alongside genotype. The review suggests that the same logic could be applied to other inherited disorders where conventional trials are constrained by small numbers and genetic heterogeneity. In those settings, disease models that reflect patient-specific biology may help determine whether a therapy should be advanced, refined, or abandoned.
The appeal is easy to understand. Rare genetic diseases often force clinicians and researchers to work with incomplete evidence, small cohorts, and highly variable phenotypes. A platform that captures how a person’s cells respond to treatment can narrow uncertainty without waiting for a large trial that may never be feasible. For regulators, laboratories, and clinicians, that creates a more credible bridge between molecular diagnosis and therapeutic action.
Still, theratyping is not a substitute for clinical outcomes. Functional recovery in a dish does not always translate into durable benefit in the airway, pancreas, or other affected organs. Assay standardization, model selection, and the interpretation of borderline responses remain critical issues. A result that appears convincing in one platform may not carry the same weight in another if the cellular context differs.
The next step is stronger translational alignment
The review’s broader message is that cystic fibrosis research now serves as a testing ground for precision medicine methods that could travel well beyond one disease. Theratyping links patient-derived biology to therapeutic selection in a way that conventional genotype-based decision-making cannot always achieve. Advanced models such as organoids and organ-on-a-chip platforms may further improve the predictive value of those assessments, especially for rare variants where clinical evidence is thin.
What remains unresolved is how best to standardize these systems so that results can support real-world prescribing with confidence. The field still needs clearer agreement on which assays should guide decisions, how to compare readouts across laboratories, and how to connect ex vivo response to meaningful clinical benefit over time. Those questions will shape whether theratyping becomes a niche research tool or a routine component of cystic fibrosis care.